NCI Eyes Some Budget Gains for FY2007

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

Congress finally resolved the current federal budget in mid-February, 4 months after fiscal year (FY) 2007 began, and raised the National Institutes of Health's funding to $28.9 billion, an increase of $619.5 million (2%) over its FY2006 appropriations.

BETHESDA, Maryland—Congress finally resolved the current federal budget in mid-February, 4 months after fiscal year (FY) 2007 began, and raised the National Institutes of Health's funding to $28.9 billion, an increase of $619.5 million (2%) over its FY2006 appropriations. Although Congress kept the National Cancer Institute's budget at $4.79 billion, the Institute gained approximately $42.8 million in additional dollars because it will not have to contribute to the NIH common fund this year. These dollar gains plus money from other sources should increase NCI's available dollars by $46 million, NCI director John E. Niederhuber, MD, said at a meeting of the National Cancer Advisory Board.

The money should enable NCI to provide $2.022 billion to fund 5,188 research project grants in FY2007, 16 more than in FY2006, he said. Noncompeting grants will fall to 3,878, a decrease of 14 from last fiscal year, and these grants will have no inflationary adjustments built into them. Competing grants will rise to 1,310, an increase of 30.

In his proposed budget for FY2008, President Bush asked Congress to provide NIH $28.9 billion and NCI $4.782 billion, decreases of $511 million and $11 million, respectively, from their newly approved FY2007 funding.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content